You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD5 / Lymphocyte antigen T1/Leu-1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)

Active, not recruiting
  • COL6A3 Positive
  • +3 more
  • Aldesleukin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

CTLA4 Haploinsufficency, Chronic Cytopenia Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting
  • CTLA4 Haploinsufficency
  • Chronic Cytopenia
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 24, 2022

Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)

Not yet recruiting
  • Lymphomas
  • B-cell Lymphomas
  • Houston, Texas
    The University of Texas M D Anderson Cancer Center
Mar 6, 2023

Non-hodgkin Lymphoma,B Cell Trial (CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection)

Not yet recruiting
  • Non-hodgkin Lymphoma,B Cell
  • CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
  • (no location specified)
Feb 14, 2023

Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • CD19-targeted chimeric antigen receptor T-cell
  • Kaohsiung, Taiwan
  • +2 more
Oct 25, 2022

Non-Hodgkin Lymphoma Trial in Aurora (CD19x22 CAR T Cells)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • CD19x22 CAR T Cells
  • Aurora, Colorado
    University of Colorado Hospital
Sep 1, 2022

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +2 more
  • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
  • Calgary, Alberta, Canada
  • +5 more
Jul 18, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • Cyclophosphamide (Non-IMP, Lymphodepletion)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +4 more
Jul 24, 2023

Metastatic Malignant Tumor in the Liver, Metastatic Uveal Melanoma Trial in Houston (Aldesleukin, Autologous CD8+

Active, not recruiting
  • Metastatic Malignant Neoplasm in the Liver
  • Metastatic Uveal Melanoma
  • Aldesleukin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 20, 2023

Multiple Myeloma Trial in Orange, Sacramento, Oklahoma City (STI-1492)

Recruiting
  • Multiple Myeloma
  • STI-1492
  • Orange, California
  • +2 more
Jan 12, 2023

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)

Not yet recruiting
  • Lymphoma, B-Cell
  • CD19 and CD22 targeted CAR-T cells
  • Langfang, Hebei, China
    Hebei Yanda Ludaopei Hospital
Dec 6, 2022

Multiple Myeloma, Allogeneic Stem Cell Transplantation Trial in Spain (CARTemis-1)

Not yet recruiting
  • Multiple Myeloma
  • Allogeneic Stem Cell Transplantation
  • CARTemis-1
  • Santander, Cantabria, Spain
  • +4 more
Aug 1, 2023

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

T-Cell Acute Lymphoblastic Leukemia/Lymphoma Trial in Beijing (CD5 CAR T (CT125B))

Recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoma
  • CD5 CAR T (CT125B)
  • Beijing, Beijing, China
    Beijing Gaobo Boren Hospital
Aug 3, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Duarte

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
  • +7 more
  • Duarte, California
    City of Hope Medical Center
Apr 5, 2023

Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL) Trial in Canada, United States (CC-97540)

Active, not recruiting
  • Lymphoma Non-Hodgkin
  • +2 more
  • CC-97540
  • Birmingham, Alabama
  • +13 more
Oct 28, 2022

Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in Houston (biological, drug, other)

Active, not recruiting
  • Metastatic Melanoma
  • Stage IV Cutaneous Melanoma AJCC v6 and v7
  • Aldesleukin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 2, 2022

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022